These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10607223)

  • 1. Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years.
    Guerret S; Desmoulière A; Chossegros P; Costa AM; Badid C; Trépo C; Grimaud JA; Chevallier M
    J Viral Hepat; 1999 Mar; 6(2):125-33. PubMed ID: 10607223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment.
    Piccinino F; Felaco FM; Sagnelli E; Aprea L; Messina V; Pasquale G; Filippini P; Scolastico C
    Res Virol; 1998; 149(5):283-91. PubMed ID: 9879606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon.
    Toccaceli F; Laghi V; Capurso L; Koch M; Sereno S; Scuderi M;
    J Viral Hepat; 2003 Mar; 10(2):126-33. PubMed ID: 12614469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method.
    Yagura M; Murai S; Kojima H; Tokita H; Kamitsukasa H; Harada H
    J Gastroenterol; 2000; 35(2):105-11. PubMed ID: 10680665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment.
    Dufour JF; DeLellis R; Kaplan MM
    Dig Dis Sci; 1998 Dec; 43(12):2573-6. PubMed ID: 9881484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term histological prognosis and serum fibrosis markers in chronic hepatitis C patients treated with interferon.
    Kojima H; Hongo Y; Harada H; Inoue T; Miyaji K; Kashiwagi M; Momose T; Arisaka Y; Fukui H; Murai S; Tokita H; Kamitsukasa H; Yagura M; Katsu K
    J Gastroenterol Hepatol; 2001 Sep; 16(9):1015-21. PubMed ID: 11595066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C.
    Karino Y; Toyota J; Sugawara M; Miyazaki K; Kuwata Y; Yamazaki K; Sato T; Ohmura T; Matsushima T
    J Gastroenterol Hepatol; 2003 Apr; 18(4):404-10. PubMed ID: 12653888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.
    Zarski JP; Sturm N; Desmorat H; Melin P; Raabe JJ; Bonny C; Sogni P; Pinta A; Rouanet S; Babany G; Cheveau A; Chevallier M
    Liver Int; 2010 Aug; 30(7):1049-58. PubMed ID: 20492512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up.
    Knolle PA; Kremp S; Höhler T; Krummenauer F; Schirmacher P; Gerken G
    J Viral Hepat; 1998 Nov; 5(6):399-406. PubMed ID: 9857349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term retreatment in chronic hepatitis C patients who were non-responders to an initial course of interferon-alpha 2b.
    Tong MJ; Blatt LM; Tong LT; Sayadzadeh K; Conrad A
    J Viral Hepat; 1998 Sep; 5(5):323-31. PubMed ID: 9795916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
    Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
    Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study of interferon therapy modified by pre-treatment viral load in cirrhotic patients. Tokyo-Chiba Hepatitis Research Group.
    Shiratori Y; Moriyama M; Imazeki F; Ohkubo H; Tanaka N; Arakawa Y; Yoshida H; Yokosuka O; Shibuya A; Matsuzaki K; Hashimoto E; Hayashi N; Hirata K; Ohashi Y; Omata M
    Liver; 2000 Jul; 20(4):271-80. PubMed ID: 10959805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-beta-1a with or without sustained viral response.
    Rao HY; Wei L; Li J; Zhang LF; Chen HY; Zhu LM; Liu F; Sun Y; Wang H
    Hepatogastroenterology; 2009; 56(90):328-34. PubMed ID: 19579592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C.
    Schvarcz R; Glaumann H; Reichard O; Weiland O
    J Viral Hepat; 1999 May; 6(3):237-42. PubMed ID: 10607236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon-alpha: histological evaluation by a modified histological activity index scoring system.
    Ninomiya T; Yoon S; Hayashi Y; Sugano M; Kumon Y; Seo Y; Shimizu K; Kasuga M
    J Gastroenterol Hepatol; 1998 Jan; 13(1):68-74. PubMed ID: 9737575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics.
    Everson GT; Jensen DM; Craig JR; van Leeuwen DJ; Bain VG; Ehrinpreis MN; Albert D; Joh T; Witt K
    Hepatology; 1999 Jul; 30(1):271-6. PubMed ID: 10385666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A short induction regimen of interferon-alpha is not effective for treatment of relapse in chronic hepatitis C: a randomized trial. For the multicentre GER-CYT-01 group.
    Poynard T; Daurat V; Chevret S; Moussalli J; Degos F; Bailly F; Borotto E; Buffet C; Bartolomei-Portal I; Richardet JP; Riachi G; Calmus Y; Bréchot C; Vidaud M; Olivi M; Bedossa P; Riffaud PC; Chastang C
    J Viral Hepat; 1999 Sep; 6(5):381-6. PubMed ID: 10607254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group.
    Cavalletto L; Chemello L; Donada C; Casarin P; Belussi F; Bernardinello E; Marino F; Pontisso P; Gatta A; Alberti A
    J Hepatol; 2000 Jul; 33(1):128-34. PubMed ID: 10905596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy.
    Sakaida I; Nagatomi A; Hironaka K; Uchida K; Okita K
    Am J Gastroenterol; 1999 Feb; 94(2):489-96. PubMed ID: 10022652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.